Actelion Ltd. rose the most in more than 17 months after winning U.S. approval for the lung drug Opsumit, giving the Swiss company a successor to a best-selling medicine that loses patent protection in late 2015.
Two days after President Barack Obama canceled plans to meet Russian President Vladimir Putin in Moscow next month, their foreign and defense ministers met in Washington today in an effort to bridge differences.
Actelion Ltd., the Swiss drugmaker that gets almost 90 percent of sales from a treatment for a rare lung disease, raised its full-year profit forecast as second- quarter sales beat estimates and it cut spending.
Actelion Ltd., the Swiss drugmaker that gets almost 90 percent of sales from a treatment for a rare lung disease, said Andre Muller will replace Chief Financial Officer Andrew Oakley, who is leaving the company.
Roche Holding AG delayed development of the experimental diabetes drug taspoglutide by at least 12 to 18 months after more people than expected suffered from side effects such as skin reactions and digestive symptoms.